Open access
Open access
Powered by Google Translator Translator

Oncology (all articles)

RCT | Perioperative nivolumab plus chemotherapy increases pathological response vs. chemotherapy alone in stage III NSCLC

10 Jul, 2023 | 13:27h | UTC

Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Addition of Neoadjuvant Nivolumab to Platinum-Based Chemotherapy in Stage III NSCLC – The ASCO Post

 

Commentary on Twitter

 


RCT | Brachytherapy alone sufficient for intermediate-risk prostate cancer, no FFP improvement with additional EBRT

7 Jul, 2023 | 16:06h | UTC

Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

News Release: Addition of EBRT to brachytherapy did not improve outcomes for men with intermediate-risk prostate cancer, brachytherapy alone remains standard of care – NRG Oncology

 


RCT | FOLFOXIRI-Bevacizumab shows promise as first-line treatment in unresectable colorectal cancer metastases

5 Jul, 2023 | 01:02h | UTC

First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group – The Lancet Oncology (link to abstract – $ for full-tetxt)

 


Scoping Review | High correlation of positive outcomes in oncology meta-analyses with industry funding

3 Jul, 2023 | 14:21h | UTC

Scoping Review: High Correlation of Positive Outcomes in Oncology Meta-analyses with Industry Funding – JAMA Network Open

 


Consensus Paper | Colorectal neuroendocrine tumors

30 Jun, 2023 | 14:45h | UTC

European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours – Journal of Neuroendocrinology

 


SR | Drivers of emergency department use among oncology patients in the era of novel cancer therapeutics

30 Jun, 2023 | 14:35h | UTC

Drivers of Emergency Department Use Among Oncology Patients in the Era of Novel Cancer Therapeutics: A Systematic Review – The Oncologist

 


FIGO staging of endometrial cancer: 2023

29 Jun, 2023 | 13:53h | UTC

FIGO staging of endometrial cancer: 2023 – Gynecology & Obstetrics

 


Perspective | Ensuring ethical postprogression therapy for patients in randomized trial control arms

28 Jun, 2023 | 13:16h | UTC

Ensuring Ethical Postprogression Therapy for Patients in Randomized Trial Control Arms – Journal of Clinical Oncology

 

Commentary on Twitter

 


RCT | Total breast reconstruction with autologous fat transfer using an expansion device vs implants in patients with breast cancer

28 Jun, 2023 | 13:12h | UTC

Effect of Total Breast Reconstruction With Autologous Fat Transfer Using an Expansion Device vs Implants on Quality of Life Among Patients With Breast Cancer: A Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)

See also: Visual Abstract

Author Interview: Effect of Breast Reconstruction With Autologous Fat Transfer vs Implants on Quality of Life – JAMA

 


SR | Medically assisted hydration in palliative care: uncertain effects on quality of life and survival

27 Jun, 2023 | 13:47h | UTC

Summary: The Cochrane Review analyzed Randomized Controlled Trials (RCTs) to evaluate the impact of Medically Assisted Hydration (MAH) on the Quality of Life (QoL) and survival of adults receiving palliative care. A total of four studies involving 422 participants, all diagnosed with advanced cancer, were considered. Two studies compared MAH with placebo, and two compared it with standard care.

The primary outcome was QoL, assessed through validated scales, with survival and adverse events being secondary outcomes. Mean differences (MD) and risk ratios (RR) were calculated for continuous and dichotomous outcomes, respectively. However, results were inconclusive due to a very low certainty of evidence. Hence, it is unclear whether MAH improves QoL, prolongs survival, or leads to adverse events when compared to placebo or standard care.

The findings are only applicable to inpatients with advanced cancer at the end of life and do not transfer to other adults in palliative care with non-cancer, dementia, or neurodegenerative diseases, or those with an extended prognosis. The lack of high-quality evidence leaves clinicians to make decisions based on perceived benefits and harms for individual circumstances.

Article: Medically assisted hydration for adults receiving palliative care – Cochrane Library

 


M-A | Effectiveness of physical therapy in axillary web syndrome after breast cancer

27 Jun, 2023 | 13:28h | UTC

Effectiveness of physical therapy in axillary web syndrome after breast cancer: a systematic review and meta-analysis – Supportive Care in Cancer

 


Perspective | Early-stage lung cancer: using circulating tumor DNA to get personal

26 Jun, 2023 | 00:38h | UTC

Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal – Journal of Clinical Oncology

 


Review | How to treat diffuse large B-cell lymphoma: oncologic and cardiovascular considerations

26 Jun, 2023 | 00:33h | UTC

How to Treat Diffuse Large B-Cell Lymphoma: Oncologic and Cardiovascular Considerations – JACC: CardioOncology

 

Commentary on Twitter

 


Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions

26 Jun, 2023 | 00:31h | UTC

Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions – CA: A Cancer Journal for Clinicians

 


Review | Treatment options in HER2-low breast cancer and proposed treatment sequencing algorithm

26 Jun, 2023 | 00:27h | UTC

A review of treatment options in HER2-low breast cancer and proposed treatment sequencing algorithm – Cancer

 


Cohort Study | Adiposity impacts cancer risk differently in males and females

22 Jun, 2023 | 15:08h | UTC

Adiposity and sex-specific cancer risk – Cancer Cell

News Release: Cancer has an obesity-related risk factor, and it depends on sex and cancer type – Cell Press

 


Cohort Study | Steady reduction in breast cancer mortality from 1993-2015 in England

22 Jun, 2023 | 14:58h | UTC

Breast cancer mortality in 500 000 women with early invasive breast cancer in England, 1993-2015: population based observational cohort study – The BMJ

Invited Commentary: Risk of breast cancer death after a diagnosis of early invasive breast cancer – The BMJ

News Release: Women diagnosed with early breast cancer today are much less likely to die from the disease than 20 years ago – University of Oxford

 

Commentary on Twitter

 


Updated Guidance | Diagnosis and treatment of Early and locally advanced breast cancer

22 Jun, 2023 | 14:52h | UTC

Early and locally advanced breast cancer: diagnosis and management – National Institute for Health and Care Excellence

 


ESTRO-ACROP guideline | Recommendations on implementation of breath-hold techniques in radiotherapy

22 Jun, 2023 | 14:51h | UTC

ESTRO-ACROP guideline: Recommendations on implementation of breath-hold techniques in radiotherapy – Radiotherapy and Oncology

 


SR | Supportive care interventions for managing gastrointestinal symptoms following treatment for colorectal cancer

22 Jun, 2023 | 14:49h | UTC

Supportive care interventions for managing gastrointestinal symptoms following treatment for colorectal cancer: a systematic review – Journal of Cancer Survivorship

 


Cohort Study | Stopping immunotherapy in patients that are progression-free at 2 years seems feasible in advanced NSCLC

21 Jun, 2023 | 13:19h | UTC

Association Between Duration of Immunotherapy and Overall Survival in Advanced Non–Small Cell Lung Cancer – JAMA Oncology (link to abstract – $ for full-text)

News Release: Real-World Data Suggests Stopping Immunotherapy after Two Years is Reasonable in Patients with Advanced Lung Cancer – Penn Medicine

 

Commentary on Twitter

 


RCT | Fruquintinib extends median survival to 7.4 months vs. 4.8 months with placebo in refractory metastatic colorectal cancer

19 Jun, 2023 | 14:02h | UTC

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study – The Lancet (link to abstract – $ for full-text)

 

Commentary on Twitter questioning the control group (thread – click for more)

 


Review | mRNA-based cancer therapeutics

19 Jun, 2023 | 13:53h | UTC

mRNA-based cancer therapeutics – Nature Reviews Cancer

 

Commentary on Twitter

 


RCT | Cisplatin–gemcitabine improves 3-year progression-free survival in N2–3 nasopharyngeal carcinoma compared to cisplatin–fluorouracil

16 Jun, 2023 | 14:05h | UTC

Concurrent chemoradiotherapy followed by adjuvant cisplatin–gemcitabine versus cisplatin–fluorouracil chemotherapy for N2–3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

News Release: Concurrent Chemoradiotherapy Followed by Adjuvant Cisplatin-Gemcitabine for the Treatment of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma – ESMO

 

Commentary on Twitter

 


RCT | Increased detection of metastases via PET-CT alters treatment path in locally advanced breast cancer

16 Jun, 2023 | 14:02h | UTC

Impact of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer – Journal of Clinical Oncology (link to abstract – $ for full-text)

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.